Pulmonx Corporation (LUNG) Financial Statements
Pulmonx Corporation (LUNG) reported trailing twelve-month revenue of $87.4M (down 3.4% year on year) and net income of -$48.1M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$30.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LUNGPulmonx CorporationFollow LUNG — free
—
Price chart with a free account
- Market cap
- 78.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 27 Oct, in 3 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue | 32.7 | 48.4 | 53.7 | 68.7 | 83.8 | 90.5 | 87.4 | |
| Gross profit | 21.2 | 35.6 | 39.9 | 50.8 | 62.0 | 67.1 | 67.4 | |
| Research & development | 7.5 | 13.1 | 15.4 | 18.1 | 17.6 | 19.5 | 19.4 | |
| Operating income | -32.3 | -47.3 | -58.6 | -61.9 | -57.7 | -53.7 | -46.3 | |
| Pre-tax income | -32.0 | -48.3 | -58.6 | -60.3 | -55.9 | -53.4 | -47.5 | |
| Income tax | 0.2 | 0.3 | 0.4 | 0.6 | 0.5 | 0.6 | 0.6 | |
| Net income | -32.2 | -48.7 | -58.9 | -60.8 | -56.4 | -54.0 | -48.1 | |
| Diluted EPS ($) | -3.16 | -1.35 | -1.59 | -1.60 | -1.44 | -1.33 | -1.16 | |
| Diluted shares (mn) | — | 36.1 | 37.1 | 38.0 | 39.1 | 40.7 | — |
USD millions · SEC XBRL
Pulmonx Corporation — questions
- What is Pulmonx Corporation's revenue?
- $87.4M over the twelve months to 2026-06-30, down 3.4% year on year, from its 10-Q and 10-K filings.
- What is Pulmonx Corporation's net income?
- -$48.1M over the twelve months to 2026-06-30.
- What is Pulmonx Corporation's free cash flow?
- -$30.7M over the twelve months to 2026-06-30.
- What are Pulmonx Corporation's diluted earnings per share?
- $-1.16 over the twelve months to 2026-06-30.
Every figure on this page comes from Pulmonx Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.